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ABSTRACT   
Objective: Patient-centered approaches to improving medication adherence hold promise, but evidence 
of their effectiveness is unclear. This review reports the current state of scientific research around 
interventions to improve medication management through four patient-centered domains: shared 
decision-making, methods to enhance effective prescribing, systems for eliciting and acting on patient 
feedback about medication use and treatment goals, and medication-taking behavior.  
Methods: We reviewed literature on interventions that fell into these domains and were published 
between January 2007 and May 2013. Two reviewers abstracted information and categorized studies by 
intervention type.   
Results: We identified 60 studies, of which 40% focused on patient education. Other intervention types 
included augmented pharmacy services, decision aids, shared decision-making, and clinical review of 
patient adherence. Medication adherence was an outcome in most (70%) of the studies, although 50% 
also examined patient-centered outcomes.   
Conclusions:  We identified a large number of medication management interventions that incorporated 
patient-centered care and improved patient outcomes. We were unable to determine whether these 
interventions are more effective than traditional medication adherence interventions.  
Practice Implications: Additional research is needed to identify effective and feasible approaches to 
incorporate patient-centeredness into the medication management processes of the current health care 
system, if appropriate. 
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1. Introduction 
Nearly 70% of Americans are prescribed at least one prescription drug, and 20% use five or more [1]. 
Medications have become a central component of the treatment of many diseases; however, 20% to 
30%  of prescriptions are never filled, and of those prescriptions that are filled, roughly half are not 
taken as prescribed [2]. These gaps in adherence result in an estimated $100 billion to $290 billion 
annually in avoidable health care costs [3-6]. Patients do not take prescribed medications for many 
reasons, including poor prescribing practices that create burdensome and complex regimens, concerns 
about cost and side effects, doubts about the benefit of medications, and low health literacy [7].   
 
Interventions have attempted to increase medication adherence and related outcomes using a variety of 
approaches. Recent reviews of this literature found that the most effective medication adherence 
interventions adopted comprehensive approaches, involved several strategies, were high-intensity, and 
were tailored to individual patients [8-10]. However, these reviews also noted the low strength of 
evidence for many interventions and a need for more research to establish value and show 
improvements in health outcomes as a result of improved adherence [8-10]. Patient-centered 
approaches may represent a foundation upon which to develop new medication adherence 
interventions and enhance those that exist, but with the intent of also improving clinical outcomes, 
patient experience, and satisfaction with medication use.   
 
The Agency for Healthcare Research and Quality (AHRQ)-funded Centers for Education and Research on 
Therapeutics (CERTs) program conducts research and provides education to advance the optimal use of 
drugs and medical devices, and biological products; increase awareness of the benefits and risks of 
therapeutics; and improve quality while cutting the costs of care.  In 2012, the CERTs focused on how 
patient-centered care could be incorporated into efforts to improve medication management and 
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related outcomes among chronically ill patients. This initiative culminated in a workshop that brought 
together patients, providers, researchers, and other stakeholders to identify innovations, successes, and 
needs in the research and implementation of strategies to improve medication management through 
patient-centered approaches (McMullen, 2013, submitted in parallel – citation forthcoming). These 
approaches included four domains of the medication management process: shared decision-making, 
methods to enhance effective prescribing, systems for eliciting and acting on patient feedback about 
medication use and treatment goals, and support for medication-taking behavior (the traditional scope 
of adherence research).  As part of this effort, we undertook a review of the literature to describe the 
current state of scientific research on patient-centered approaches to medication management. This 
paper summarizes the results of our review.  
 
2. Methods 
 
2.1. Design 
 
2.1.1. Patient-centered medication management framework  
This literature review outlined for attendees of the workshop the “state of the science” in patient-
centered approaches to improving medication management. Prior to the workshop, drawing on the 
scientific literature and their own expertise, a steering group of CERTs researchers who have worked on 
adherence but have diverse backgrounds (medicine, pharmacy, informatics, epidemiology) as well as 
two patient representatives developed the “Patient-Centered Medication Management (PCMM)” 
framework to serve as the foundational concept to guide this literature review, as well as the 
workshop’s agenda and prioritization process. The PCMM framework sought to describe a process 
through which patient-centered care—defined as care that is respectful of and responsive to individual 
patient preferences, needs, and values and that ensures patient values guide all clinical decisions [11]—
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is incorporated into practices that support medication prescribing and use. This framework outlined a  
number of activities related to medication management that  included (1) shared decision-making, (2) 
methods to enhance effective prescribing, and (3) systems for eliciting and acting on patient feedback 
about medication-taking and treatment goals, and (4) medication-taking behavior.  
 
Within the PCMM framework, shared decision-making refers to a process that results in decisions that 
are shared by providers and patients, informed by the best evidence available, and weighted according 
to the specific characteristics and values of the patient. The shared decision-making approach has been 
linked most frequently with therapeutic and screening decisions. However, in this context, shared 
decision-making refers to engaging the patient in prescribing decisions by communicating why a 
medication is indicated, its risks and benefits, and the likely imp ct on the patient’s health.  
 
Effective prescribing includes discussion of solutions to patients’ perceived barriers to obtaining and 
taking medications that are part of an agreed-upon treatment plan. The ultimate goal of effective 
prescribing is to have the patient understand how and when the medication is to be taken. 
 
Effective patient feedback interventions address unanticipated barriers and answer new questions that 
may come up as a patient proceeds with a prescribed treatment regimen. Effective feedback is 
facilitated by patient-provider communication, followed by an efficient process to modify the treatment 
plan if needed. 
 
Medication-taking behavior interventions use effective (accessible, understandable, and useful) tools 
to inform patients and enhance accurate medication-taking, provide systems and resources that aid 
patients in obtaining medications in a timely and consistent manner, and offer options to help patients 
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with medication-taking at home.  The medication-taking behavior component encompasses many of the 
interventions that address the traditional concept of medication adherence.  
 
Collectively, these domains reflect the CERTs efforts to move beyond medication adherence and 
recognize the shift in perspective from the provider to the patient and the movement towards outcomes 
other than adherence that are important to patients. These include health outcomes, patient knowledge 
of and confidence in treatment regimens, patient satisfaction with care, and quality of patient-provider 
communication.  
 
 2.1.2. Search strategy 
We performed a systematic search of publications describing the implementation and evaluation of 
interventions that incorporate at least one of the four PCMM domains (shared decision-making, 
effective prescribing, effective feedback, or medication-taking behavior) to improve medication 
management. Our search identified articles published in peer-reviewed medical journals between 
January 1, 2007, and May 31, 2013. We limited our search to the time period from 2007 forward to 
capture the current “state of the science” in patient-centered medication management. Searches were 
conducted using the Ovid MEDLINE and PubMed databases. We also scanned bibliographies of pertinent 
systematic and narrative reviews to identify relevant publications not captured by our search strategy 
[9;12].  
 
Key words and phrases used in our search strategy are provided in Appendix 1. We used terms related 
to the type of study (e.g., “clinical trial,” “pretest,” “time series”), prescription drugs (e.g., “drug,” 
“medication,” “prescribing”), patient-centeredness (e.g.,  “patient preference,” “patient focused,” 
“shared decision-making”), and adherence (e.g., “adherence,” “compliance,” “medication adherence,” 
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“treatment adherence”).  We used a Boolean approach to combine key words that indicated study type, 
outcomes, and a focus on medication use and patient-centered care. Search terms and parameters were 
adjusted for each database while maintaining a common overall structure. Search results were 
combined and screened for duplicate entries.  
 
2.1.3. Selection of studies 
We conducted an initial review of abstracts to determine their eligibility for full article review. We 
included articles in the full review if they described a randomized controlled trial, pragmatic trial, or 
quasi-experimental design that evaluated the implementation of an intervention to improve medication 
management and related outcomes through one of the PCMM framework components. We did not 
restrict studies by the type of outcome being measured; studies were not required to measure 
adherence as an outcome. Studies were English language only. 
 
2.1.4. Data abstraction and synthesis 
We created a data abstraction tool to collect a broad range of information, including intervention type, 
study design, clinical area, the health care provider who delivered the intervention, and measurement of 
outcomes. Two members of the research team independently applied our abstraction tool to articles 
that met the criteria for full review. A third reviewer resolved differences.   
 
Our use of the PCMM framework as a guiding principle for this review allowed us to include a wide 
range of interventions targeting diverse outcomes. However, the framework domains were reflective of 
a continuous process for the management of prescribing and medication-taking and, thus, were 
overlapping. Therefore, although we could identify interventions based on the framework, we found it 
difficult to categorize interventions into mutually exclusive groups based on the framework. To account 
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for difficulty in the application of the framework and to provide structure to the discussion of results, 
interventions were categorized by the primary intervention type or approach through which researchers 
sought to impact the steps outlined in the PCMM framework. These intervention types were informed 
by the expertise of the steering group, are similar to intervention types reported in previous reviews of 
medication adherence interventions, and were collected as part of the abstraction process.  We report 
interventions categorized into the following intervention types: (1) educational interventions, (2) 
augmented pharmacy services, (3) decision aids or shared decision-making, (4) case management, and 
(5) pharmacist or physician access to adherence or clinical outcome information and monitoring of 
medication-taking behaviors (i.e., feedback interventions).  
 
We examined whether interventions focused on adherence, clinical, or patient-centered outcomes. 
Adherence measures varied widely, and included rates measured through prescription fills, pill counts, 
electronic monitoring, medication possession ratio (MPR), as well as self-report medication adherence 
scales. Clinical outcomes included measures that indicate a patient’s disease status, such as cholesterol 
levels, depression symptom scores, or blood glucose levels. While alleviation of clinical symptoms, 
improvement in disease status, and successful adherence to medication regimens are clearly important 
to patients, for the purposes of this review, we defined a patient-centered outcome as an outcome of 
importance to patients but not inclusive of adherence or clinical measures (e.g., blood pressure). 
Examples of these outcomes included patient knowledge, quality of life, satisfaction, perceived control 
of symptoms, self-efficacy, understanding of treatment benefits and risks, and perceived barriers to 
medication use. We included hospitalization, mortality, and cost outcomes separately.  We then 
qualitatively summarized the characteristics and outcomes of these interventions. 
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Although we collected data to describe the impact of interventions, study methodologies, outcome 
measurement, populations studied, and clinical focus, the studies were too heterogeneous to perform a 
formal meta-analysis. Thus, quantitative comparisons of effect sizes and discussion comparing study 
design and measurement methodology were outside the scope of this paper. 
 
3. Results 
 
3.1. Results of literature search 
 
Using our search strategy, we identified 536 citations; manual searches of systematic reviews and other 
sources added 65 citations (Figure 1). After screening abstracts for eligibility and exclusion criteria, we 
reviewed 133 full-text articles. Following full-text review, 60 articles represented unique studies and 
were included. Of those, 43 were individual or cluster-randomized controlled trials, four were pragmatic 
trials, and 13 employed quasi-experimental study designs. Seven of the 13 quasi-experimental studies 
utilized a before-and-after design methodology, while the remaining six studies employed interrupted 
time series or other retrospective designs.  
 
3.2. Description of Interventions and Impact on Outcomes 
Interventions were categorized by the primary intervention type, as follows: (1) educational 
interventions delivered with or without additional behavioral or social support [13-28], through 
counseling [29-31], health coaching [32;33], or motivational interviewing [34;35], or in combination with 
feedback on clinical values, involving patients in self-monitoring, or e-health [36-38] (Table 1); (2) 
augmented pharmacy services [39-50] (Table 2); (3) decision aids or shared decision-making [51-59] 
(Table 3); (4) case management [60-67] (Table 4); and (5) feedback of adherence or clinical values to 
pharmacists or physicians or monitoring of medication-taking behaviors [68-72] (Table 4).  
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Interventions were delivered by a diverse group of professionals and, in many cases, more than one 
health care professional. Physicians, pharmacists, and multidisciplinary teams delivered interventions in 
14, 12, and 11 studies, respectively. Physicians most often delivered decision aids, shared decision-
making interventions, and educational interventions. Pharmacists were the only health care 
professionals to engage patients in augmented pharmacy services. The clinical conditions most 
frequently targeted by these interventions were cardiovascular diseases—including hypertension, atrial 
fibrillation, and heart failure. Other commonly targeted illnesses included diabetes and asthma. Time for 
patient follow-up after the intervention ranged from one-time measurements to five years, with a 
median duration of six months.  
 
Nearly all of the studies evaluated the impact of the intervention on more than one outcome, although 
medication adherence was assessed most commonly, in 43 of the 60 studies. Studies also focused on 
patient-centered outcomes such as quality of life, patient knowledge, and patient satisfaction (34 
studies); clinical outcomes including measures of disease status such as blood pressure, cholesterol 
levels, and depression symptom scores (26 studies); hospitalization or mortality outcomes (nine 
studies); and medication utilization (eight studies) or cost to patients or health plans (five studies). 
 
3.2.1. Patient education interventions 
 
Educational interventions provided information to patients about already prescribed medication 
regimens and often resulted in better medication adherence and greater patient knowledge.  The 
benefits of these interventions were most evident in their impact on patient-centered outcomes such as 
patient knowledge, self-efficacy, and self-monitoring skills. The most successful educational 
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interventions combined patient education with efforts such as coaching or behavioral and social 
support.  
 
Twenty-six of the 60 studies reported on educational interventions, with or without additional 
components such as behavioral or social support (Table 1). The majority of these interventions (16 of 26 
studies) focused on medication-taking [13;17-20;23-28;30;31;34;36;37], while five addressed effective 
prescribing [16;22;29;35;38], four utilized shared decision-making [14;15;32;33], and one addressed 
effective feedback [21]. Educational interventions were frequently delivered by research personnel or 
multidisciplinary teams. These interventions were commonly repetitive and occurred over varied 
periods of time, ranging from weeks to years, making comparison difficult.  
 
Sixteen of the 26 educational intervention studies examined medication adherence as an outcome. 
Patients receiving education typically had higher adherence rates than patients receiving usual care. 
However, in a number of studies, the intervention produced no significant long-term impact on 
adherence when compared to patients not receiving the intervention [19;23;25;31;35]. For example, 
Pladevall et al. reported a 30% increase in medication adherence following education supplemented by 
adherence monitoring and provision of social support, although the control group also improved 
adherence by 20% and both groups attained approximately 90% adherence upon study completion [25]. 
Several studies reported diminishing adherence rates over study follow-up. For example, in one study, 
patients who participated in group educational meetings had a 26% decrease in adherence over the 
course of study follow-up. However, in the same study, patients who received education on an 
individual basis experienced a similar 25% decline in adherence [14]. In fact, a number of studies noted 
that significantly higher adherence rates among intervention versus control patients were attributed 
only to a slower decline in adherence over time among intervention patients [14;23;24;27;31].  
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Patient-centered outcomes were measured in 14 educational interventions, with 11 studies reporting 
significant improvements in one or more of these outcomes. Four studies reported adherence 
improvements as well as increased patient knowledge, self-efficacy, and self-monitoring skills; 
reductions in barriers to adherence; and greater patient activation [20;24;27;33]. Notably, for these 
outcomes, successful interventions combined patient education with supplemental coaching, 
motivational approaches, or social support.  
 
Seven of the nine educational intervention studies that measured clinical outcomes found significant 
improvements in the management of diabetes [13;33;35], hypertension [17;25], mental health among 
rheumatoid arthritis patients [26], and fracture risk among osteoporosis patients [37]. Two studies 
examined hospitalization among hypertensive patients; one of these studies resulted in decreased 
hospitalization [21], while one did not [19], despite having interventions that were relatively similar in 
intensity.  Finally, only one of four studies to examine mortality outcomes found a significant survival 
benefit [28].  
 
Six studies provided insight into resource investment and patient selection associated with educational 
interventions. Homer et al. found that the provision of information in group settings rather than on an 
individual basis led to better adherence and lower rates of drug discontinuation, while using fewer 
health care resources and incurring lower costs to patients and health plans [14]. In other studies, 
authors noted that educational interventions might be most cost-effective among less-adherent 
populations [19] and most effective in improving outcomes among patients with an acute event [13], 
patients with a shorter time since diagnosis and initial prescribing [26], patients with high health literacy 
[26], and patients who are “ready for change” [33;37]. However, the lack of consistency among the 
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studies in design and measures limits the ability to draw general conclusions about subgroup-specific 
effectiveness and cost savings. 
 
3.2.2. Augmented pharmacy services interventions 
Augmented pharmacy services studies commonly targeted medically complex patients, identified 
barriers to already prescribed medication use, and documented effects on outcomes after initial 
treatment decisions were made. The benefits of these interventions were most evident in the tailoring 
of medication regimens to ongoing patient needs and in cost reduction. Many pharmacy interventions 
were tailored to specific patient needs and delivered by pharmacy staff on a one-on-one basis; however, 
patient-centered outcomes were rarely measured.  
 
Augmented pharmacy services interventions primarily targeted elderly patients with multiple comorbid 
conditions who were taking several medications (Table 2). The majority of these interventions (eight of 
12 studies) focused on medication-taking [39;41;44-46;49;50], while three addressed effective 
prescribing [42;47;48] and two centered on effective feedback [40;43]. Generally, these interventions 
were delivered by pharmacists or pharmacy staff and provided tailored information and tools to patients 
that allowed for adjustment of regimens to match patient needs. Interventions commonly involved 
multiple avenues for interaction with patients, including face-to-face and telephone encounters. 
Although the majority of these interventions included populations with complex medication needs, a 
number of interventions focused on specific chronic conditions [41;42;45-47;50] or specific medications 
[41].  
 
Evidence supporting the interventions’ effectiveness in improving medication adherence was mixed, 
although significant positive changes [41;45-48;50] were observed more often than negative or non-
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significant findings [39;42]. Patient-centered outcomes were less likely to be measured than clinical or 
adherence outcomes following pharmacy interventions; however, when assessed, patients were often 
satisfied with their interactions with pharmacists and with potential cost savings. Overall, patient cost 
and utilization outcomes were measured following augmented pharmacy services more frequently than 
for any other type of intervention. There appeared to be a trend toward reduced costs to patients 
[39;44;47;48;50]; however, Welch et al. reported increased medication costs following a medication 
review and counseling intervention [49]. Welch et al. noted that addressing important safety issues such 
as drug-drug interactions, identification of medication gaps, and under-treatment resulted in 
improvements in medication regimens and patient adherence; however, patient costs also increased 
[49]. In contrast, Pindolia et al. reported reductions in total prescriptions per patient per month and 
reduced pharmacy costs after implementing an intervention that invested only 2.5 hours of telephone 
contact per patient [48]. Longer-term costs may have been lowered through improved treatment but 
were not assessed in these studies. 
 
3.2.3. Decision aids and shared decision-making interventions 
We found that decision-making interventions most closely fit the paradigm of patient-centered care. 
These interventions were implemented at the time of prescribing and often resulted in increased 
patient knowledge, although there was little evidence for impact on ongoing decision-making or 
improvements in adherence or clinical outcomes. 
 
Nine studies employed decision aids or shared decision-making (SDM) as the principal component of 
their interventions (Table 3). [51-59]. These interventions were most often delivered by physicians 
during face-to-face health care encounters and were designed to provide patients with information 
about potential treatment choices and their associated benefits and risks.  
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Decision aid and SDM interventions are typically designed to inform choice rather than change behavior 
[55;58]. Accordingly, the measurement of patient knowledge was common (eight of the nine studies) 
and improvements were noted in seven studies [51-56;58]. Three studies measured and showed 
improvements in patient participation, confidence in decision-making, and satisfaction with care 
[53;54;56].  Three studies reported that patients’ understanding of risk was improved and decisional 
conflict lessened [52;54;55]. However, authors observed that increased patient knowledge did not 
change the patient decision-making process, and there was little evidence that treatment choice or 
patient beliefs changed even when patients were more informed about benefits and risks [52-55;57;58]. 
This suggests that patients may have a wide range of considerations when making treatment decisions, 
not just medical facts; however, these studies did not report on the range of considerations or the basis 
for patient decision-making. For example, Thomson et al. found that patient uptake of warfarin actually 
decreased despite a reduction in decisional conflict [52], although the study did not report the patient 
perspective on what led to this outcome. Two of the four studies in this category that sought to increase 
medication adherence resulted in improvements [51;54]. Only one of the three studies that sought to 
improve clinical outcomes identified improvements [51]. In fact, Montori et al. noted that there is little 
evidence that decision aids improve adherence, and concurrently, that there is limited opportunity to 
improve clinical outcomes following decision aid use [54].  
 
3.2.4. Case management interventions 
Case management interventions commonly employed individualized assessments of patient barriers to 
medication-taking and tailored approaches to address these barriers. However, the limited number of 
studies and the wide variation in both the approaches used and resources dedicated to these 
interventions make it difficult to draw any conclusions about overall effectiveness.  
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In eight case management intervention studies (Table 4), nurses and care teams delivered the 
intervention. Four of eight studies focused on medication-taking [60;61;66;67], three studies focused on 
effective feedback [62-64], and one focused on effective prescribing [65]. Case management 
interventions targeted patients with a wide variety of clinical conditions. All studies that measured 
adherence found either significant improvement in adherence among patients who received the 
intervention [60-62;65;67]. In addition, four of eight case management studies examined clinical 
outcomes; all four of these resulted in significant improvements [60;61;64;66]. Last, two case 
management studies measured quality of life and found no effect [60;63].   
 
3.2.5. Feedback interventions 
These interventions intended to utilize feedback to foster further discussion of current treatment 
regimen with the patient as a means to inform changes to these regimens.  Five studies provided 
pharmacists or physicians with information regarding patient medication adherence and clinical status 
through health information technology, direct patient report, or medical record review (Table 4). Of 
these interventions, two focused on effective feedback [68;71], two concentrated on medication-taking 
behavior [70;73], and one centered on effective prescribing [69]. Interventions employing feedback and 
access to medication adherence information were most commonly conducted among patients with 
hypertension [70;71] or patients undergoing care for psychiatric illness or depression [68;69;72]. Two of 
the five studies showed an increase in patient satisfaction regarding care and concordance between 
patient preferences and prescribed regimens [69;72]. Wilder et al. found that psychiatric patients were 
more likely to adhere to medications if they received treatments that they preferred, thus underlining 
the importance of patient preference in medication decision-making and effectiveness [69]. 
 
Page 18 of 44
Ac
ce
pte
d M
an
us
cri
pt
 
18 
 
4. Discussion and Conclusion 
 
4.1. Discussion 
Our review describes the extent to which current medication management interventions incorporate 
elements of patient-centeredness. Our use of the PCMM framework as a guiding principle allowed us to 
include a wide range of interventions targeting diverse outcomes. However, we found it difficult to 
meaningfully and consistently categorize interventions into mutually exclusive groups based on the 
framework’s domains, because they are overlapping: shared decision-making, effective prescribing, 
effective feedback, and medication-taking behavior. This suggests that our framework may better serve 
as a template for improving how providers and patients engage in medication management  than as a 
structure for studying this process in the scientific literature. In addition, the studies were 
heterogeneous and results were difficult to collectively interpret. Thus, we could not draw firm 
conclusions as to whether patient-centered medication management interventions represent a distinct 
shift away from or an improvement over more traditional medication adherence interventions.  Rather, 
we provide a broad description of interventions, the approaches they took to engage patients, and their 
contribution to the improvement of outcomes, with the intent of informing the development of future 
efforts.  
 
A number of comprehensive reviews of medication adherence interventions have been published. A 
recent evidence review found that a variety of interventions led to adherence improvements, with 
interventions to reduce out-of-pocket expenses, case management, and educational interventions the 
most effective across clinical conditions [8]. The authors noted that the majority of efforts to improve 
adherence did not examine patient-reported outcomes, and when better adherence was observed, 
there was little evidence of improvement in patients’ health outcomes [8]. Our review generally 
supports this view.  
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Our review was different from previous reviews because we focused on patient engagement and 
patient-centered approaches, allowed for observational study designs, and included patient-centered 
outcomes. Patient knowledge, patient satisfaction, and quality-of-life outcomes were the most 
commonly-included patient-centered outcomes and were measured in 34 of the 60 articles reviewed. 
However, additional concepts central to the process of patient-centered care, such as preference for 
treatment regimens and patients’ health care goals, were rarely reported. This may be due to difficulties 
in measuring these processes and outcomes, such as the lack of widely applied and validated methods.  
Although all of the included interventions were deemed to be patient-centered, the most common focus 
was still medication adherence. A variety of interventions observed improvements in adherence over 
the follow-up period; however, since average follow-up was less than one year, we do not know the 
optimal length of time over which an intervention should be implemented or the sustainability of 
intervention effects over time. In turn, there were inconsistent results for a link between adherence and 
clinical outcomes improvement.  
 
Interventions were delivered by a diverse group of health care providers, either by individuals or as part 
of collaborative or coordinated care.  Many interventions were carried out at one level within a health 
care visit or setting (e.g., augmented pharmacy services, decision aids, or shared decision-making 
interventions), despite recognition of the importance of collaborative or coordinated care in the 
medication adherence literature. For interventions that did incorporate collaborative care, the 
participation of personnel not otherwise present in the health care system (e.g., study personnel) was 
common, thus limiting their generalizability.  
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We found that many studies included small patient samples with very specific clinical and therapeutic 
needs. Small sample sizes may be due to the high level of tailoring required or the difficulty in 
systematically developing and carrying out individualized interventions. Furthermore, with the 
exception of augmented pharmacy services interventions, patients with complex medication needs were 
often excluded, reducing the potential “real-world” applicability. In addition, many efforts were  likely 
expensive, although details of cost and time commitment were not commonly reported; in most cases, 
the impact on health care-provider time and the complexity of coordination would also limit 
generalizability. Finally, interventions were implemented with a focus on specific aspects of medication 
management; studies did not typically address medication management starting at the prescribing 
decision and extending to appropriate medication-taking behavior. Thus, combinations of these 
interventions may be needed to provide long-term impacts on p tient outcomes.  
 
Our review has a number of limitations. We based our literature search on our PCMM framework, which 
was informed by the Institute of Medicine’s definition of patient-centered care. We also identified 
previously published reviews and search strategies that attempted to ascertain patient-centeredness 
within the scientific literature. Despite these efforts, since the concept of patient-centered care is 
relatively new and continuously evolving, we may have missed relevant articles.  
 
In addition, we included studies from different populations and clinical settings, with different disease 
emphases, and differing methodology and measurement. Thus, quantitative comparisons of effect sizes 
and discussion comparing study design and measurement methodology were outside the scope of this 
paper. Finally, our summary may suffer from publication or reporting bias, as we found few articles that 
reported negative results for all outcomes measured.  
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4.2. Conclusions 
Our review identified efforts to involve patients in medication prescribing and use. Evidence supporting 
overall effectiveness of interventions was sparse.  Furthermore, there was limited evidence of improved 
patient-centered outcomes or clinical endpoints and sustained improvement in outcomes. Variability in 
the delivery of interventions and outcomes measured precluded concrete comparisons between 
interventions or comparisons with traditional medication adherence interventions. In general, it is not 
clear that patient-centered medication management interventions represent an improvement over 
more traditional medication adherence interventions.   
 
4.3 Practice Implications and future research   
Additional research is needed to examine how to integrate patient-centered care into medication 
management. This requires the development of definitions and methods to standardize the 
measurement of adherence and patient-centered outcomes, to allow for comparisons of interventions. 
Also, future study teams may want to consider incorporating qualitative research methods to provide 
detail regarding how patient-centered care is delivered and how patient-centeredness is perceived and 
received by patients. Finally, we encourage additional research within different populations with 
different clinical needs, that assesses the effectiveness of specific intervention types as well as 
combinations of intervention types, and that assesses the resources needed to address both initial and 
chronic medication management issues. These efforts would help foster the identification of effective 
and feasible approaches to incorporate patient-centeredness into the medication management 
processes of the current health care system, if appropriate. 
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Figure 1. Study selection criteria and flow diagram. 
 
 
 
536 articles identified through 
MEDLINE search 
Screening 
Eligibility 
Included 
Identification 65 articles identified through scan 
of systematic reviews 
601 unique articles
601 unique articles 468 abstracts excluded
133 full-text articles assessed 
for eligibility 
73 full-text articles excluded, did not
meet inclusion criteria (did not 
address a PCMM component or 
was not evaluative)
60 studies included in qualitative 
synthesis  
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Table 1. Educational interventions to improve patient-centered medication management.  
Study Intervention Description Clinical area 
Interventio
n agent 
Duration of 
follow-up 
Evidence for medication adherence 
outcomes Evidence for non-adherence outcomes 
Education 
Altiner 
2007 
Education to address 
physician-patient 
misunderstandings and 
empower patients 
Outpatient 
antibiotics  
Physician 6 weeks; 12 
months 
NA Rate of antibiotic prescribing: Decrease (+) 
Grosset 
2007 
Patient education about 
continuous dopaminergic 
therapy 
Parkinson's 
Disease 
Researcher 3 months IG: 17% timing adherence at baseline 
increased to 39% 
CG: 21% timing adherence increased to 20%  
(p=0.007) 
 
The difference in timing adherence pre- to 
post-intervention between the 2 groups was 
13.4% (p=0.002). 
NA 
Homer 
2009  
Group versus individual 
education  
Rheumatoid 
arthritis 
Nurse 12 months Pill counts, at follow-up: 90% adherence 
among group vs. 69% among individual 
counseling (p=0.06) 
 
Self-reported adherence, at follow up: 97% in 
group vs. 94% among individual counseling 
(p=1.0) 
 
DMARD use among individual counseling 
group decreased from 63% at 4 months to 
38% at 12 months; decreased among group 
counseling from 73% at 4 months to 47% at 
12 months (p=0.42, NS at 4 months; p=0.61, 
NS at 12 months) 
Patient satisfaction: NS 
Nielsen 
2010 
Group-based educational 
program 
Osteoporosis Multi-
disciplinary 
team 
3,12, and 24 
months 
 
Adherence at 
24 months 
IG: 100% self-reported adherence at baseline 
decreased to 92% 
 
CG: 100% adherence decreased to 80% 
 
Significantly higher adherence among IG 
(p<0.006) 
Patient knowledge: Increase (+) 
Park 2010 Employer-based education 
program with telephone 
follow-up 
Asthma Care 
managers 
6 months NA Adherence barriers: Decrease (+) 
Asthma control: Increase (+) 
Days of work limited by asthma, days that 
activities were missed or limited: Decrease (+) 
Table
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Rudd 2009 Education to reduce literacy 
barriers, enhance health 
outcomes, and increase self-
efficacy 
Inflammatory 
arthritis 
Arthritis 
educator 
6 and 12 
months 
Adherence through 4-item measure on Levine 
questionnaire: 
IG: 0.40 (SD, 0.40) adherence decreased to 
0.17 (SD, 0.25) at one year; 12.21% decrease 
 
CG: 0.30 (SD, 0.37) adherence decreased to 
0.18 (SD, 0.30) at one year -- 3.12% decrease 
 
CO (mental health score): Decrease (+) 
Self-efficacy, satisfaction with care: NS 
Appointment keeping: NS 
Education and behavioral support 
Bocchi 2008  Repetitive education and 
telephone monitoring 
Heart failure Care team Mean follow-
up=2.47 years 
NA Mortality: NS 
Unplanned hospitalizations, days of 
hospitalization, emergency care: Decrease (+) 
Edworthy 
2007 
Comprehensive program 
including education and self-
monitoring 
Cardiovascular 
disease 
Care team 19 months At 19 months of follow-up: 
ACEIs: 92% among IG vs. 91% among CG 
(p=NS) 
Beta-blockers: 89% among IG vs. 80% among 
CG (p<0.01) 
ASA: 92% among IG vs. 89% among CG (p=NS) 
Lipid-lowering agents: 83% among IG vs. 78% 
among CG (p<0.05) 
Warfarin: 97% among IG vs. 97% among CG 
(p=NS) 
Re-hospitalization, hospital days: NS 
Crude mortality: NS 
Hacihasano
glu 2011  
Patient-oriented education 
on healthy lifestyle and 
medication adherence and 
in-home monitoring 
Hypertension Nursing 6 months NA CO (BP): Decrease (+)  
Health-promoting lifestyle scores: Increase (+) 
Medication adherence self-efficacy (MASE):  
 Group A (general & med adherence 
education, clinic & home visits) - MASE: 
55.3 increased to 71.1 
 Group B (Group A interventions plus 
healthy lifestyle behavior education) - 
MASE: 55.55 increased to 72.27 
 Group C (Usual care) - MASE: 55.12 
increased to 56.85 
p<0.005 at post-test (test among three 
groups) 
 
*MASES: medication adherence efficacy scale; 
26-item questionnaire with range of scores 
from 26 (low) to 78 (high) 
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Janson 
2009 
Self-management education 
on long-term adherence 
Asthma Nurse, 
respiratory 
therapist 
14 weeks  IG: 82% adherence at baseline 
decreased to 77% after 14 weeks 
 CG: 80% adherence at baseline 
decreased to 73% at 14 weeks 
IG 9-times greater odds than CG of more than 
60% adherence (p=0.02) 
 
Mean adherence decreased over time in both 
groups although decline was less in IG (p=NS) 
Perceived asthma control: Increase (+) 
McCarthy 
2013 
Providing prescription 
information or services to ED 
patients; three intervention 
groups: (1) practical services 
to reduce barriers to 
prescription filling; (2) 
consumer drug information 
from MedlinePlus; or 
(3) both services and 
information  
Emergency care Researcher 1 week Overall 88% primary adherence by self-report: 
 CG: 87% 
 Practical group: 88% 
 MedLine group: 87%  
 Combination group: 88% 
No clinically meaningful differences in primary 
adherence by drug class, by whether the drug 
was prescribed as needed, or by over-the-
counter status or by whether the drugs 
treated an underlying condition. 
NA 
Moshkovsk
a 2011 
Multi-faceted intervention, 
including educational and 
motivational components 
plus options including 
simplified dosing regimens 
and practical reminders 
Ulcerative 
colitis (5-ASA 
therapy) 
Researcher 48 weeks Baseline adherence (measured through urine 
concentration) overall: 76%  
Baseline adherence of 80% among IG vs. 71% 
among UC (p=0.30) 
Follow-up adherence at 48 weeks 76% among 
IC vs. 32% among UC (p=0.0001) 
Patient satisfaction with information: Increase 
(+) 
Wu 2012 Education intervention 
including Medication Event 
Monitoring System (MEMs) 
feedback 
Heart failure Research 
staff 
9 months 3 groups (education and MEMs feedback, 
education only, usual care):  
 
Baseline adherence (defined as rate at or 
above 88%): 
 Education & MEMs group: 70% 
 Education only: 59% 
 CG: 64% 
(p=0.694 at baseline between groups) 
 
At 9 months:  
 Education & MEMs: 74% 
 Education only: 65% 
 CG: 36% 
 (p=0.15) 
Cardiac event-free survival: Increase (+) 
Education and social support 
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Chen 2010 Self-efficacy intervention 
program delivered through 
DVD, education booklet, and 
support group 
Asthma Care team, 
social 
support 
6 weeks Significant improvement in medication 
adherence behaviors among patients who 
received self-efficacy intervention (p = .008) 
Self-efficacy: Increase (+) 
Self-monitoring: Increase (+) 
Follow-up visits: Increase (+) 
Regular exercise: Increase (+) 
Asthma attack prevention and management: 
Increase (+) 
Pearce 
2008 
Practice-based educational 
intervention to foster 
involvement of a relative or 
friend for the reduction of 
cardiovascular risk 
Diabetes Study 
personnel, 
support 
person 
9 or 12 months  Group A (pure intervention): 50% high 
adherence; 42% medium adherence 
 Group B (intervention plus more data 
collection to explore mechanism of 
action): 29.8% high; 63.2% medium 
 Group A & B combined: 39.3% high; 
53.3% medium 
 Group C (control): 41.8% high; 49.5% 
medium 
p (A vs. B. vs. C)=0.1584 
p (AB vs. C) = 0.4358 
CO (SBP, HbA1C): NS 
HRQoL: NS 
Patient satisfaction: NS 
Perceived health competence: NS 
Pladevall 
2010 
Educational information, pill 
counts, and designation of a 
family member to support 
adherence behavior 
Hypertension Physician, 
social 
support 
Total study 
time was 5 
years (mean = 
39 months); 
adherence 
measured at 6 
months 
 IG: 61% adherence at baseline increased 
to 92.2% adherence (p=0.002) 
 CG: 69% adherence at baseline 
increased to 89% adherent at 6 months 
IG more likely than CG to be at least 80% 
adherent over 6 month period (OR=1.91; 95% 
CI: 1.19-3.05) 
CO (SBP): Decrease (+) 
5-year mortality: NS 
Education (counseling) 
Adie 2010  Motivational interviewing 
and telephone counseling 
that targeted participant-
specific goals related to 
lifestyle change 
Hypertension Researcher 6 months Overall increase from 75% taking a statin 
medication to 84% at 6 months (p=0.02) 
CO (SBP): NS 
CO (Cholesterol): Decrease (+) 
Medication knowledge: Increase (+) 
Number of BP medications: NS 
Perahia 
2008 
Telephone adherence 
support intervention 
Depression Health care 
professiona
l  
12 weeks At study close, IG adherence of 92.6% vs. CG 
adherence of 92.1% 
CO (depression remission): NS 
Efficacy measures: NS 
Taitel 2012 Community-based 
pharmacist-led face-to-face 
counseling among new statin 
users 
Statin use Pharmacist 12 month  IG: 87.6% MPR at 2 months decreased to 
63.5% at 12 months 
 CG: 84.8% MPR decreased to 58.9% at 
12 months 
IG had significantly higher MPR than CG at 
end (p<0.01) 
NA 
Education (health coaching) 
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Ho 2012 Face-to-face communication 
skills training 
Complementar
y or alternative 
medications 
(CAM) 
Researcher 2 physician 
visits 
NA Discussion of CAM with physician: Increase (+) 
Wolever 
2010 
Integrative health coaching 
to create an individualized 
vision of health, goals chosen 
to align with patient values 
Diabetes Health 
coach 
6 months Adherence measured using Morisky scale: 
 IG: 6.7 (0.96) at baseline increased to 7.2 
(0.97) (p=0.004 for change over time) 
 CG: 6.7 (1.25) at baseline increased to 
6.9 (1.25) (change over time NS) 
Difference in adherence among IG and CG at 6 
months NS 
CO (A1C): Decrease (+)  
Barriers to adherence: Decrease (+) 
Patient activation, perceived social support, 
and benefit finding: Increase (+) 
Exercise frequency, stress, perceived health 
status: Decrease (+) 
Education (motivational interviewing) 
Finocchario
-Kessler 
2012 
Motivational interviewing 
and modified directly-
observed therapy (DOT) 
Antiretroviral 
medication use 
Nurse 48 weeks NA Knowledge: Increase (+) 
Rubak 2011 Motivational interviewing Diabetes Physician 1 year No difference between prescriptions written 
and filled for blood glucose lowering, BP, or 
lipid lowering medications among IG and CG  
 
Significant improvement in adherence among 
both groups from baseline to one year; nearly 
100% adherence in both groups at one year 
CO (HbA1C): Decrease (+) 
Education (with feedback of clinical values, involving patients in self-monitoring, or e-health) 
Delmas 
2007  
Physician education and 
reinforcement using 
feedback of bone turnover 
markers 
Osteoporosis Physician 1 year Medication persistence: higher among those 
with positive clinical values; changes in 
adherence NS for stable or poor clinical values 
 
One-year persistence through electronic 
monitoring: 80% among IG versus 77% among 
UC (p=0.160) 
CO (new fractures): Decrease (+) 
Nassaralla 
2009 
Education to improve patient 
participation in medication 
reconciliation and 
performance feedback and 
training to health care team 
Primary care Health care 
team 
Follow-up: 1 
month 
 
 
NA Completeness and correctness of medication 
lists: Increase (+) 
Neafsey 
2011 
E-health tailored education 
program  
Hypertension Nurse 4 months  
(4 visits; one 
per month) 
NA Patient knowledge/self-efficacy: Increase (+) 
Patient satisfaction with care: Increase (+) 
Treatment intensification: + (lower need for 
intensification among intervention group) 
 
IG = intervention group 
CG = control group 
NA = not applicable 
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UC = usual care 
DMARDs = disease-modifying anti-rheumatic drugs 
NS = result not significant 
+ = statistically significant positive change in outcome 
SD = standard deviation 
CO = clinical outcomes 
ASA = aspirin 
MA = medication adherence 
BP = blood pressure 
SBP = systolic blood pressure 
HRQoL = health-related quality of life 
MPR = medication possession ratio  
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Table 2. Augmented pharmacy services interventions to improve patient-centered medication management.  
 
Study Intervention description Clinical area 
Intervention 
agent 
Duration of 
follow-up Evidence for medication adherence outcomes 
Evidence for non-adherence 
outcomes 
Calvert 2012 In-hospital counseling, 
attention to adherence 
barriers, communication of 
discharge medications, 
inclusion of community 
pharmacist in continued 
monitoring 
Coronary heart 
disease - aspirin, 
beta-blockers, and 
statin use 
Pharmacist, 
with 
feedback to 
physician 
6 months Adherence self-report (aspirin, beta blocker & 
stain) at 6 months: 91% in IG vs 94% in CG 
(p=0.50) 
 
Refill records (beta-blockers & statins): IG 53% 
vs. CG 38% (p=0.11) 
NA 
Elliott 2008 Pharmacist telephone 
follow-up and advice 
Chronic disease 
(diagnosis of 
cardiovascular 
disease, diabetes, 
asthma, or 
rheumatoid 
arthritis) 
Pharmacist  4 weeks Non-adherence: 9% among IG vs. 16% among CG 
(p<0.05) 
Medication-related problems: 
Decrease (+) 
Mean patient costs: Decrease (+) 
Less costly, more efficient 
Eussen 2010 Pharmacy-based care 
program to educate 
patients about importance 
of medication adherence 
and association between 
adherence and clinical 
outcomes 
Statin use Pharmacist 12 months  At 6 months: 11% of IG and 16% of CG had 
discontinued 
 At one year: 23% discontinuation among IG 
vs. 26% among CG (HR 0.84, 95% CI: 0.65-
1.10, p=NS) 
 One-year MPR: 99.5% among IG vs. 99.2% 
among CG (p=0.14) 
CO (Total cholesterol): Decrease (+) 
CO (LDL cholesterol): Decrease (+) 
 
 
Hunt 2008 Active management by 
pharmacists in the primary 
care setting 
Hypertension Pharmacist 12 months  IG: 61% in self-reported high adherence 
group at baseline; increased to 67% at end 
(p=0.08) 
 CG: No increase in adherence over study 
(p=0.52) 
 At one year: 67% in IG report high 
adherence vs. 69% in CG (p=0.77) 
CO (BP): Decrease (+) 
Knowledge: NS 
QoL: NS 
Satisfaction: NS 
Klein 2009 Enhanced pharmaceutical 
care program  
Liver 
transplantation 
Pharmacist 12 months 90% dosing compliance among IG vs. 81% among 
usual care (p=0.015) 
CO (Target blood levels): Decrease (+) 
Lenaghan 207 Home-based pharmacist 
medication review with 
feedback to physician 
Elderly taking 4+ 
medications 
Pharmacist, 
with 
feedback to 
physician 
6 months NA Hospital or care home admissions: NS 
Mortality: NS 
QoL: NS 
Fewer medications in IG 
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Monte 2009  Clinical pharmacy 
education, clinical 
assessment, provider 
recommendations and 
follow-up 
Diabetes Pharmacist 1 year NA CO (glycosolated hemoglobin, fasting 
glucose): Decrease (+)  
CO (BMI, HDL cholesterol, LDL 
cholesterol, Total cholesterol): NS 
Costs: NS 
Moore 2013 Medication therapy 
management program 
Chronic disease 
(including asthma, 
diabetes, heart 
failure, or heart 
disease) 
Pharmacist One year Condition-specific changes in MPR %:  
 
Hypertension: IG 2.29 vs CG -2.31 (p<0.001) 
Dyslipidemia: IG 2.10 vs CG -2.61 (p<0.001) 
Diabetes: IG 1.64 vs CG -0.73 (p=0.112) 
Depression: IG 1.23 vs CG 0.07 (p=0.420) 
Asthma: IG 2.33 vs CG 1.71 (p=0.739) 
Plan-paid health care costs: Decrease 
(+) 
Hospitalization: Decrease (+) 
Emergency room visits: NS 
ROI: Increase (+) 
Phumipamorn 
2008 
Extended pharmacy services 
including education on 
appropriate lifestyles and 
correct diet with pamphlet 
outlining disease 
complications, targets of 
treatment, lifestyle 
changes, and medications 
Diabetes Pharmacist 8 months Percent pill count:  
 IG: 81.8%  pill count increased to 88.6%;  
mean difference 6.8% (p=0.005) 
 CG: 87.2% pill count decreased to 84.4% ; 
mean difference -2.8% (p=0.29) 
Baseline within-group percent pill count 
difference significant (p=0.05) 
 
Between-groups percent pill count mean 
difference significant (p=0.004) 
CO (A1C): NS 
CO (Cholesterol): Decrease (+) 
Diabetic knowledge scores: Increase 
(+) 
Pindolia 2009 Medication management 
therapy program  
Medicare patients 
with selected 
chronic diseases, at 
least 2 
prescriptions, and 
high annual 
prescription drug 
costs 
Pharmacist 12 months ACE/ARB: 10% increase among IG (MTM); 1% 
decrease among CG (i.e., patients who declined 
MTM) 
 
Beta-blocker: 2% decrease among IG; 8% 
decrease among CG 
CO (GI bleed): Decrease (+) 
CO (LDL in coronary artery disease, 
HbA1c values < 7% in diabetes): Trend 
towards decrease (+) 
Patient cost: Decrease (+) 
Shimp 2012 Medication therapy 
management program that 
incorporated medication 
action plan to incorporate 
patient preferences for 
problem resolution  
Multiple comorbid 
conditions 
Pharmacist 4 months, 12 
months 
Baseline MPR for IG and CG: Range 84-96% 
 
No significant changes over time for IG or CG 
Drug cost: Decrease (+) 
Welch 2009  Medication therapy 
management program for 
home-based Medicare 
beneficiaries 
Medicare 
beneficiaries with 
chronic disease, 
high medication 
costs and utilization 
Pharmacist 180 days NA Mortality: Decrease (+) 
Hospitalization: Increase (-) 
Medication costs: Higher cost (-) 
 
IG = intervention group 
CG = control group 
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NA = not applicable 
+ = significant positive change in outcome 
NS = result not significant 
SD = standard deviation 
CO = clinical outcomes 
MPR = medication possession ratio 
BP = blood pressure 
QoL = quality of life 
BMI = body mass index 
ROI = return on investment 
ACE = angiotensin-converting-enzyme inhibitor 
ARB = angiotensin receptor blockers 
MTM = medication therapy management 
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Table 3. Decision aids and shared decision-making interventions to improve patient-centered medication management. 
 
Study Intervention description Clinical area 
Intervention 
agent 
Duration of 
follow-up 
Evidence for medication adherence 
outcomes Evidence for non-adherence outcomes 
Decision aids 
Fagerlin 2010 Decision aid to impact 
knowledge and attitudes 
towards tamoxifen use 
Breast cancer Physician Immediate NA Understanding of risks & benefits: 
Increase (+) 
Initiation of therapy: NS 
Kasper 2008  Patient decision aid  Multiple sclerosis Physician 6 months NA Concordance of roles: NS 
Treatment choice: NS 
Mann 2009 Statin Choice decision aid  Statin use among 
diabetic patients 
Physician 3 and 6 
months 
80% of participants reported good 
adherence at 6 months (p=NS between 
groups) 
Understanding of risk (with or without 
stain use): Increase (+)  
Montori 2011 Osteoporosis Choice 
decision aid  
Osteoporosis Physician 6 months  44% of IG received bisphosphonate 
at baseline vs. 40% of CG  
 100% of IG had > 80% adherence at 
6 months compared to 74% of CG 
(p=0.009) 
Understanding of risk: Increase (+) 
Patient involvement: Increase (+) 
Mullan 2009  Diabetes Medication 
Choice aid 
Diabetes Physician 6 months Adherence self-report after decision aid: 
76% among IG vs. 81% among CG [95% 
CI): 0.74(0.24 to 2.32)] 
 
Persistence & days covered: significantly 
lower in IG 
CO (HbA1c): NS 
Patient knowledge, involvement: 
Increase (+) 
Thomson 2007 Computerized decision aid 
to assist with decision to 
take warfarin or aspirin 
therapy 
Atrial fibrillation 
and anti-
thrombotic 
therapy 
HIT 3 months  NA CO: NS 
Decisional conflict: Decrease (+) 
Care services: NS 
Shared decision-making 
Deinzer 2009 Shared decision-making 
versus patient education 
for patient empowerment 
Hypertension Physician 1 year NA CO (BP): NS 
Loh 2007 Multi-faceted program 
including physician 
training, a decision board 
for use during the 
consultation, and printed 
patient information 
Depression Care team 6-8 weeks Medication adherence rate: NS CO (Depression severity): NS 
Patient participation, patient 
involvement: Increase (+) 
Patient satisfaction: Increase (+) 
Consultation time: NS 
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Wilson 2010 Shared decision-making 
(SDM) versus clinician 
decision-making (CDM) 
Asthma Physician 2 years Refill adherence measured as continuous 
medication acquisition (CMA) = total days 
supplied divided by 365 days 
 
Pre-randomization: 22.2% acquired LABA 
at least once, 11% acquired an ICS-LABA 
combo 
 
At 2 year: SDM (shared decision-making) 
had CMA=0.52;  
CDM (clinician decision-making) had 
CMA=0.43 (p=0.0346, compare with 
SDM);  
CG had CMA=0.42 (p=0.0296, compare 
with SDM) 
CO (health care use, rescue medication 
use): Decrease (+) 
CO (lung function): Increase (+) 
Asthma control: Increase (+) 
Asthma-related QoL: Increase (+) 
NA = not applicable 
+ = significant positive change in outcome 
NS = non-significant 
IG = intervention group 
CG = control group 
CO = clinical outcomes 
BP = blood pressure 
LABA = long-acting beta agonists 
ICS-LABA = inhaled corticosteroid/long-acting beta agonist 
QoL = quality of life 
CMA = continuous medication acquisition  
 
Page 42 of 44
Ac
ce
pte
d M
an
us
cri
pt 
1 
 
Table 4. Additional interventions to improve patient-centered medication management. 
Study Intervention description Clinical area 
Intervention 
agent 
Duration of 
follow-up Evidence for medication adherence outcomes Evidence for non-adherence outcomes 
Case management 
Bogner 
2012 
Integrated care management to 
offer education and guideline-
based recommendations  
Primary care Care 
managers, 
physicians 
12 weeks  IG: Improved oral hypoglycemic adherence 
from 35.9% with >80% adherence to 65%  
 CG: decreased from 42% to 31% (p<0.001) 
CO (HbA1C): Decrease (+) 
CO (Depression remission): Increase (+) 
Chimbanrai 
2008  
Involving health care provider 
and patient to improve 
adherence, including monthly 
visits and directly-observed 
therapy  
Tuberculosis Care team, 
social support 
6 months NA CO (rate of cure): Increase (+) 
Patient knowledge: Increase (+) 
Gelmanova 
2011 
Care team, home visits, and 
directly-observed therapy 
Tuberculosis Care team Median 
program 
time: 245 
days (IQR 
147-345) 
Baseline adherence of 52% increased to 81%; 
56% increase in dosing compliance  
NA 
Gensichen 
2009 
Structured telephone interview 
to monitor disease symptoms 
and support medication 
adherence, with feedback to 
physician 
Depression Health care 
assistant 
feedback to 
physician 
12 months 12-month Morisky score of 2.7 among IG vs. 2.53 
among CG (mean difference 0.17) (p=0.042) 
CO (Depression symptoms): Decrease (+) 
QoL: NS 
Hudson 
2008 
Communication and follow-up 
to identify barriers to adherence 
with follow-up to tailor 
strategies to overcome barriers 
Schizophrenia Nurse 6 months  CG (Basic education) baseline adherence 
increased from 45.5% to 60.6% 
 IG (Enhanced education) increased from 
42.8% at baseline to 65.3% at follow-up 
At baseline, no difference between groups 
(p=0.667); at follow-up: OR=1.94 (95% CI=1.08 to 
3.48) 
NA 
Olsson 
2012 
Two interventions: (1) home 
visit by study nurse; (2) home 
visits and letter with 
prescription review sent to 
physician; and (3) nurse home 
visits, prescription review to 
physician and a current and 
comprehensive medication 
record sent to patient 
Primary care Nurse 12 months NA Prescription quality: NS 
QoL, HRQoL: NS 
Polypharmacy: NS 
Stanhope 
2013 
Person-centered planning, 
including extensive counseling 
and monitoring, documentation 
of patient personal goals, and 
the development of service 
plans and strategies to meet 
patient goals 
Mental health Physician 11 months  IG: adherence increased by 2% per month 
over the 11-month period (B=.022, p<.01). 
 CG: No significant change in rate of 
adherence (B=.004, p<.25) 
At 11 months, the rate of adherence for the CG 
lower than IG.   
 
Appointment-keeping: Increase (+) 
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Rate of change in medication adherence for IG 
and CG differed significantly (p<.01).  
Wakefield 
2011 
Nurse-managed home 
telehealth intervention 
Diabetes and 
hypertension 
Nurse, HIT 12 month No adherence numbers reported. Authors 
reported that there was no significant difference 
between IG and CG. 
CO (A1C): NS 
CO (SBP): Decrease (+) 
Feedback interventions 
Chang 2012 Feedback of patient-reported 
disease severity to physicians 
Depression Physician 3 months NA Treatment modification: NS 
Christensen 
2010 
Electronic reminder and 
monitoring device 
Hypertension HIT 12 months Self-reported compliance:  
 At 6 months, IG (group 1) at 90.6% vs. CG 
(group 2) at 85.1% (NS) 
 At 12 months, IG (group 2) at 86.3% vs. CG 
(group 1) at 88.4% (NS) 
CO (BP): NS 
Rinfret 
2009  
Information technology-
supported management 
program and feedback between 
patients and primary care 
providers 
Hypertension HIT feedback 
to physician 
12 months  Adherence composite index (continuous 
medication availability (CMA) times no of anti-
hypertension drugs): 1.36 in IG vs. 1.00 in CG at 
12 months (p=0.008) 
CO (BP): Decrease (+) 
Dose adjustment: Increase (+) 
More antihypertensive meds at end of 
study. 
Simon 2011 Online messaging to provide 
monitoring and counseling for 
care management 
Depression HIT 4 months; 
90 days for 
adherence   
Number (%) using an antidepressant for over 90 
days: 81% among IG vs. 61% among CG 
(p=0.001) 
 
Number receiving an additional antidepressant: 
22% among IG vs. 16% among CG (p=0.27) 
CO (depression scores): Decrease (+) 
Satisfaction with care: Increase (+) 
Wilder 
2010 
Advanced directive to 
determine patient preferences 
and treatment choice 
Psychiatry Physician  12 months Receiving at least one requested medication 
predicted greater adherence at 12 months (OR: 
7.8, 1.8-34.0, p<0.01). 
Concordance between patient 
preference and prescribing: Increase (+) 
IG = intervention group 
CG = control group 
+ = significant positive change in outcome 
CO = clinical outcomes 
NA = not applicable 
QoL = quality of life 
NS = non-significant 
HRQoL = health-related quality of life 
SBP = systolic blood pressure 
HIT = health information technology 
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Appendix 1. Key terms used in Medline and PubMed searches.  
Study Type 
Prescriptions 
Drugs 
Patient-centeredness  Outcomes 
Clinical trial 
Controlled trial, 
randomized 
controlled trial 
Evaluation 
Pretest, posttest 
Time series 
Intervention 
Before and after 
Medication, 
medicine 
Drug 
Treatment 
Therapy 
Regimen 
Drug 
utilization  
Prescriptions
/prescribing 
Pharmacy 
Shared/sharing and decision-making/ 
decision-making/choice/behavior  
Decision aid 
Patient participation, involvement 
Patient preference/feedback/engagement, 
empowerment/goal/barrier/perspective 
Person/client/patient-
centered/focused/oriented   
 
Medication/treatment adherence, 
compliance, noncompliance, persistence, 
concordance/commitment/dose reduction/ 
discontinuation 
Patient participation, involvement 
Choice/behavior 
Patient preference/feedback/engagement, 
empowerment/goal/barrier/perspective 
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